Uridine Shows Promise: Opening New Avenues for Neurological Disease Intervention via the Gut-Brain Axis
The gut-brain axis serves as a critical bidirectional communication pathway between the gut and the brain. Many neurological disorders are accompanied by gut microbiota dysbiosis. A review published in Pharmacological Reports notes that uridine, a pyrimidine nucleoside produced naturally in the human body and also obtainable from food, acts on both the gut and brain, opening new prospects for neuroprotective drug development.
Uridine participates in RNA synthesis and cell membrane phospholipid production. It boosts synaptic plasticity, suppresses neuroinflammation and supports neuronal survival. Meanwhile, it strengthens the intestinal mucosal barrier, regulates gut microbiota and raises levels of beneficial metabolites such as short-chain fatty acids. In turn, gut microbiota modulates uridine metabolism in the body, forming a bidirectional gut-brain crosstalk.
Animal studies have demonstrated the protective effects of uridine in models of stroke, Parkinson’s disease, epilepsy and mood disorders. It works directly on brain tissue and indirectly exerts neuroprotection by reshaping the gut microenvironment. Nevertheless, most current evidence comes from animal and in vitro tests.
Industry insiders consider uridine a promising candidate for combined intervention. Further research is still needed to clarify administration routes and optimal dosages, and more human clinical trials are required to verify its clinical value for treating neurological diseases through the gut-brain axis.
FOR DETAIL: https://doi.org/10.1007/s43440-025-00788-5
Article from:
